Schedule 13D ownership disclosure

Arbutus Biopharma Corp

Common Shares, without par value · CUSIP: 03879J100

Event date: 2025-02-20

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Whitefort Capital Master Fund, LPReported CIK 0001704387

    Shares: 13,307,967.00 · Class: 7.0%

  • Whitefort Capital GP, LLC

    Shares: 13,307,967.00 · Class: 7.0%

  • Whitefort Capital Management, LPReported CIK 0001884931

    Shares: 13,307,967.00 · Class: 7.0%

  • Whitefort Capital Management GP, LLC

    Shares: 13,307,967.00 · Class: 7.0%

  • David Salanic

    Shares: 13,307,967.00 · Class: 7.0%

  • Joseph Kaplan

    Shares: 13,307,967.00 · Class: 7.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-000560
Form type
SCHEDULE 13D/A
Filer
Arbutus Biopharma Corp
CIK
CIK 1447028
Filed
Feb 21, 2025
Reporting period
Feb 20, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub